Clinical trials: Migraine, Acute
Migraine
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
- Trial name
- PIONEER-PEDS1 (NCT04396236)
- Testing
- Lasmiditan
- Where
- 152 sites in United States, Belgium and 13 more
- Volunteers
- 847 people
- Sponsor
- Eli Lilly and Company
Migraine
Timolol Eye Drops in the Treatment of Acute Migraine Headache
The goal of this study is to determine whether timolol eye drops are effective in alleviating acute migraine headaches. Subjects will be randomized to receive either timolol eye drops or placebo (tears) to use as a migraine…
- Trial name
- NCT02630719
- Testing
- Timolol eye drops, Artificial tears
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Missouri, Kansas City
Migraine
Acute Treatment of Migraine in Pre-Adolescents: Real-World Analysis of Remote Electrical Neuromodulation (REN)
Migraine is a prevalent neurological disorder that severely impacts both children and adolescents, causing significant disability.
- Trial name
- NCT06138756
- Testing
- Nerivio
- Where
- 2 sites in United States, Israel
- Volunteers
- 293 people
- Sponsor
- Theranica
Acute Migraine
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean
A randomized, double-blind, placebo-controlled parallel group study to evaluate efficacy and safety of lasmiditan tablet compared to Placebo in the acute treatment of Migraine
- Trial name
- NCT04218162
- Testing
- Lasmiditan 50mg, Lasmiditan 100mg
- Where
- South Korea
- Volunteers
- 294 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Acute Migraine Headache
Oral Medications for the Management of Acute Migraine Headache in the Emergency Department
The goal of this pilot randomized control trial is to assess the feasibility of our patient recruitment and data collection strategy ahead of a full scale RCT investigating the efficacy of oral v.
- Trial name
- NCT05983354
- Testing
- Oral metoclopramide and ibuprofen, Intravenous metoclopramide and ketorolac
- Sponsor
- Health Sciences North Research Institute
Migraine in Adults
Study of Sumatriptan Naproxen Sodium Succinate Tablets for the Treatment of Acute Migraine Attacks
A multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of sumatriptan naproxen sodium succinate tablets in the treatment of acute migraine attacks.
- Trial name
- NCT04948164
- Testing
- sumatriptan 85mg and naproxen sodium 500mg
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Peking University Third Hospital
Acute Treatment of Migraine
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
The purpose of the study is to learn about safety and how the body processes the study medicine called Zavegepant (PF-07930207) in children with a history of migraine.
- Trial name
- NCT06995729
- Testing
- Zavegepant
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- Pfizer
Migraine With Aura, Migraine Without Aura
Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache
The purpose of this study is to evaluate the effect of rizatriptan, alone or combined with caffeine for treating acute attacks of migraine. Each subject will have 3 months to treat 3 acute migraine headache attacks.
- Trial name
- NCT00471952
- Testing
- Maxalt 10mg MLT plus Caffeine 75mg
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Diamond Headache Clinic
Migraine With Aura
Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura
The following study is being conducted to explore the safety and effectiveness of a new chemical entity called NXN-188 in subjects with a history of migraine with aura.
- Trial name
- NCT00877838
- Testing
- NXN-188
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Danish Headache Center
Migraine
Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)
The purpose of this study is to investigate the efficacy and safety of MK0974 compared to a placebo for acute migraine.
- Trial name
- NCT00432237
- Testing
- MK0974 50 mg, MK0974 150 mg, MK0974 300 mg
- Volunteers
- 1,703 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine Headache
Safety and Efficacy of NPS 1776 in the Acute Treatment of Migraine Headaches
The purpose of this study was to evaluate the effectiveness and safety of a single oral dose of NPS 1776 in the acute treatment of migraine pain and associated symptoms.
- Trial name
- NCT00172094
- Testing
- NPS 1776 (800 mg), NPS 1776 (400 mg)
- Where
- 22 sites in United States
- Volunteers
- 189 people
- Sponsor
- Shire
Migraine
A Study of Lasmiditan (LY573144) Over Four Migraine Attacks
The reason for this study is to see how effective and safe the study drug known as lasmiditan is in the acute treatment of 4 migraine attacks with or without aura.
- Trial name
- NCT03670810
- Testing
- Lasmiditan
- Where
- 141 sites in United States, Austria and 15 more
- Volunteers
- 1,633 people
- Sponsor
- Eli Lilly and Company
Migraine Disorders, Heart Disease
Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)
The purpose of this study is to evaluate the safety and efficacy of telcagepant in the treatment of acute migraine in participants with stable vascular disease.
- Conditions
- Migraine Disorders, Heart Disease, Cerebrovascular Accident, TIA (Transient Ischemic Attack)
- Trial name
- NCT00662818
- Testing
- Telcagepant, Acetaminophen/Paracetamol
- Volunteers
- 165 people
- Sponsor
- Merck Sharp & Dohme LLC
Post-Acute COVID-19 Syndrome, ME/CFS
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related…
- Conditions
- Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA)
- Trial name
- NCT04806620
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Brain Inflammation Collaborative
Migraine Disorders
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
The primary objective is to evaluate the safety of long-term treatment with NP101 as assessed by: Subject self-examination skin irritation scores Adverse events Changes in vital signs and ECG parameters The secondary objective is…
- Trial name
- NP101-008 (NCT00792103)
- Testing
- NP101
- Where
- 34 sites in United States
- Volunteers
- 198 people
- Sponsor
- NuPathe Inc.
Migraine, Migraine With Aura
Gepant treAtments: EffectIveNess and tolERability (GAINER)
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as acute migraine treatment in a cohort of episodic or chronic migraine patients.
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura, Chronic Migraine
- Trial name
- GAINER (NCT05903027)
- Testing
- Rimegepant 75 MG Disintegrating Oral Tablet
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- University of Florence
Migraine, Classic Migraine
Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine
The purpose of this study is to evaluate the impact of topiramate (migraine prevention medicine) on the effectiveness of almotriptan malate (acute migraine medicine) when treating acute migraine headaches.
- Conditions
- Migraine, Classic Migraine, Common Migraine
- Trial name
- NCT00210496
- Testing
- topiramate; almotriptan malate
- Volunteers
- 406 people
- Sponsor
- Janssen-Ortho LLC
Migraine
Efficacy of Rimegepant 75 mg for the Acute Treatment of Migraine: a Bayesian Individual Participant Data Meta-analysis Standardized to Defined Target Populations
This non-interventional study will evaluate the efficacy of rimegepant 75 mg compared with placebo for the acute treatment of moderate or severe migraine attacks using individual participant data (IPD) from six completed…
- Trial name
- NCT07906262
- Testing
- Rimegepant
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Migraine
Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy
To assess the efficacy and safety of eletriptan for migraine headaches in subjects who were not satisfied with rizatriptan therapy
- Trial name
- NCT00632385
- Testing
- Eletriptan
- Where
- 16 sites in United States
- Volunteers
- 127 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Migraine
Single-Site Study of Naltrexone/Acetaminophen for the Acute Treatment of Migraine: A Phase 2 Randomized Trial
This two-stage clinical trial will assess a novel combination therapy for acute migraine. In Stage 1 (factorial), participants will receive the combination, each individual component, or placebo.
- Trial name
- AT-06 (NCT05685225)
- Testing
- Stage 1: Naltrexone/Acetaminophen, Stage 1: Naltrexone, Stage 1: Acetaminophen
- Where
- United States
- Sponsor
- Allodynic Therapeutics, Inc